MET and renal cell carcinoma: Interestingly, cabozantinib, which is a TKI directed at VEGFR2, MET and AXL (the latter being activated by anti-angiogenic TKI treatment [37]), shows superior clinical efficacy in both treatment naïve as well as VEGF inhibition refractory RCC [20], further underscoring the importance of combinatorial targeting.